We hear all about the national trend: how women from coast to coast are using weight loss medications like Ozempic and Wegovy ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

Millions hoping to get King Kong weight loss jab Mounjaro on the NHS may have their hopes dashed due the glacial NHS roll-out plan, experts have warned. Health chiefs yesterday announced 250,000 ...

The National Institute for Health and Care Excellence is consulting on a phased roll-out of Eli Lilly’s weight loss drug tirzepatide – more commonly known as Mounjaro – as NHS England looks to combat ...

Dubbed the “King Kong” of weight loss jabs, Mounjaro, the brand name for tirzepatide, is a weekly injection licensed to treat type 2 diabetes on the NHS. Trials have shown some users can lose ...

NHS estimates obesity-related conditions cost £11.4 billion per year in healthcare spending. According to the Health Survey for England 2022, about 64% of adults in the country are overweight or ...

She’s one of thousands of plaintiffs across the country claiming in a federal lawsuit that Ozempic, Mounjaro and other popular drugs prescribed for diabetes and obesity harmed their health ...

England’s National Health Service (NHS) has proposed a phased launch of Eli Lilly’s blockbuster weight loss drug Mounjaro (tirzepatide) because of the large number of patients who could ...

Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list.Yahoo Finance Senior Health Reporter Anjalee Khemlani ...

Mounjaro was authorised for obesity treatment in England in November 2023, two months after it was cleared for type 2 diabetes treatment. Image credit: Shutterstock/ M7kk. England’s National Health ...

Manufactured by Eli Lilly and Company, both Mounjaro and Zepbound contain the active ingredient tirzepatide. Tirzepatide is similar to semaglutide, which is used in medications like Ozempic, Rybelsus, ...

Biomea Fusion's lead candidate, BMF-219, shows potential in diabetes treatment but faces competition from superior GLP-1 drugs like Ozempic and Mounjaro ... 0.5% reduction in A1c, and 56% ...